Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Wassermann

Plastic Surgery Columbia, SC Medical Doctor

NPI 1336191931 CMS profile 241751

1220 Blanding St, Columbia, SC 29201

Open in the dashboard

General payments

$76,989

140 records reported · program years 2019–2025

Research payments

$250

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Wassermann of Columbia, SC is reported in the CMS Open Payments database as having received $76,989 across 140 general payments and $250 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $483 12
2024 General $202 7
2023 General $2,770 20
2022 General $1,324 21
2021 General $2,494 17
2020 General $51,960 29
2020 Research $250 1
2019 General $17,756 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Wassermann
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Richard Wassermann were reported at $483. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Richard Wassermann Plastic Surgery median Middle half National median
2019 $17,756 $371 $122–$1,483 $163
2020 $51,960 $158 $52–$438 $114
2021 $2,494 $249 $87–$752 $132
2022 $1,324 $274 $102–$793 $149
2023 $2,770 $299 $113–$891 $160
2024 $202 $361 $124–$1,062 $164
2025 $483 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. TELA Bio, Inc. $54,609 43 payments
  2. Musculoskeletal Transplant Foundation Inc. $17,953 7 payments
  3. AbbVie, Inc. $2,810 26 payments
  4. Allergan Inc. $692 34 payments
  5. Mentor Worldwide LLC $313 11 payments
  6. Sientra, Inc. $155 8 payments
  7. Merz North America, Inc. $153 1 payment
  8. Stryker Corporation $133 2 payments
  9. Zimmer Biomet Holdings, Inc. $47 1 payment
  10. Smith+Nephew, Inc. $44 3 payments
  11. Other $80 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $68,200 11 payments
  2. Food and Beverage $4,466 119 payments
  3. Travel and Lodging $4,323 10 payments
Products named General payments · program years 2019–2025
  1. OviTex $50,960 27 payments
  2. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $3,575 14 payments
  3. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $2,582 20 payments
  4. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $2,297 8 payments
  5. MemoryGel Breast Implants $268 9 payments
  6. BOTOX $243 7 payments
  7. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $234 14 payments
  8. NATRELLE $181 11 payments
  9. ALLODERM $160 4 payments
  10. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $155 8 payments
  11. Other $664 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sientra, Inc. $250 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

279

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$2,919

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

6.8%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 31 $961
Ssd Silver Sulfadiazine Brand 19 $557
Clindamycin Hcl Generic 53 $340
Silver Sulfadiazine Generic 11 $331
Scopolamine Generic 22 $240
Ondansetron Hcl Generic 41 $160
Oxycodone Hcl Generic 45 $133
Gabapentin Generic 40 $124
Cyclobenzaprine Hcl Generic 17 $73

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$10,547

Medicare's payments for the services billed

Medicare patients

26

Average age 72

Services billed

50

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 75%
Arthritis 46%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

141 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record